Vertex Pharmaceuticals (VRTX) free cash flow

Free cash flow · fiscal 2025
$3.19B

Vertex Pharmaceuticals (VRTX) generated free cash flow of $3.19B in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$978.00M. Figures as of 18 Nov 2026, 12:05 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$3.19B
Growth, 5 years
+1.3% a year
Highest on record
$3.93Bfiscal 2022
Lowest on record
-$978.00Mfiscal 2024
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Vertex Pharmaceuticals free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow grew at a compound 1.3% a year. Across the 18 fiscal years on record (2008–2025), the highest was $3.93B in fiscal 2022 and the lowest -$978.00M in fiscal 2024.

History · 18 fiscal years

Free cash flow by fiscal year

Vertex Pharmaceuticals free cash flow, year by year

Vertex Pharmaceuticals (VRTX) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$3.19B—
2024-$978.00M 129.8% down
2023$3.28B 16.5% down
2022$3.93B 63.0% up
2021$2.41B 19.5% down
2020$2.99B 100.4% up
2019$1.49B 27.2% up
2018$1.17B 57.6% up
2017$745.52M 315.2% up
2016$179.54M—
2015-$410.73M—
2014-$624.31M—
2013-$112.06M 157.0% down
2012$196.70M 80.2% up
2011$109.14M—
2010-$673.50M—
2009-$451.08M—
2008-$258.66M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

More on VRTX

Vertex Pharmaceuticals, figure by figure

Vertex Pharmaceuticals (VRTX) overview: price, valuation and scorecardAll health care companies by market value

Vertex Pharmaceuticals free cash flow: questions and answers

What is Vertex Pharmaceuticals's free cash flow?

Vertex Pharmaceuticals (VRTX) generated free cash flow of $3.19B in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$978.00M.

What is the growth rate of Vertex Pharmaceuticals's free cash flow?

Over the five fiscal years to 2025 free cash flow grew at a compound 1.3% a year.

What are the highest and lowest free cash flow figures on record for Vertex Pharmaceuticals?

Across the 18 fiscal years on record (2008–2025), the highest was $3.93B in fiscal 2022 and the lowest -$978.00M in fiscal 2024.

How is Vertex Pharmaceuticals's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Vertex Pharmaceuticals it is on record here for 18 fiscal years, 2008 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Vertex Pharmaceuticals (VRTX) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/VRTX/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.